Key facts
- Notable investors include Innoangel Fund, Unity Ventures (China), Tsinghua Innovation Ventures, Zhehua Investment, Autobio Diagnostics Company — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Renke Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Renke Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Renke Biotech
Developer of screening products designed for cancer and clinical applications. The company offers cell culture systems, genetic analysis tools, and automated laboratory processes with scalable design, high sensitivity, and compatibility across multiple research environments, enabling healthcare institutions, academic laboratories, and biotechnology enterprises to improve diagnostic accuracy, accelerate experimental workflows, enhance data reliability, and medical development while supporting long-term innovation in life sciences.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- renkebiotech.com/
- Ownership
- Privately Held (backing)
Renke Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renke Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renke Biotech in its N-PORT filings yet. We sweep new filings monthly.